Syros Pharmaceuticals Inc
NASDAQ:SYRS
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Syros Pharmaceuticals Inc
NASDAQ:SYRS
|
34.3k USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
395.1B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
204.9B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
190B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.3B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.5B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.4B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Syros Pharmaceuticals Inc
Glance View
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 124 full-time employees. The company went IPO on 2016-06-30. The firm is focused on redefending the power of small molecules to control the expression of genes. The firm is engaged in developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases, and building a clinical-stage pipeline of gene control medicine. The firm's lead product candidates include Tamibarotene, SY-2101 and SY-5609. Its Tamibarotene, is a selective retinoic acid receptor alpha (RARα), agonist RARA-positive patients with higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML). Its SY-2101, is an oral form of arsenic trioxide (ATO) being developed for the treatment of acute promyelocytic leukemia (APL). Its SY-5609, is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) which is being development for patients with select solid tumors and blood cancers.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Syros Pharmaceuticals Inc is -25 340.7%, which is below its 3-year median of -5 036.5%.
Over the last 3 years, Syros Pharmaceuticals Inc’s Net Margin has decreased from -434.2% to -25 340.7%. During this period, it reached a low of -25 340.7% on Sep 30, 2024 and a high of -368.5% on Dec 31, 2021.
